Patrick Burnett, MD, PhD, is a board-certified dermatologist and the chief medical officer of Arcutis Biotherapeutics.
Pipeline Updates on the Horizon From Arcutis Biotherapeutics
Patrick Burnett, MD, PhD, shares key updates expected in 2025 for therapeutics treating atopic dermatitis, alopecia areata, and more.
Patrick Burnett, MD, PhD, Highlights Arcutis’ New Seborrheic Dermatitis Initiative With Odell Beckham Jr.
The overwhelmingly positive feedback from both clinicians and patients reinforces the unmet need roflumilast foam is addressing in seborrheic dermatitis care.
Daily Derm Times: April 30, 2025
Expanding Topical Non-Steroidal Options in Atopic Dermatitis to Reduce Chronic Steroid Use
Optimizing Atopic Dermatitis Care With Emerging Topical Therapeutics
Q32 Bio’s Bempikibart Receives FDA Fast Track Designation for Alopecia Areata